Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGARFiled 13 h ago

Align Technology (ALGN) reports a director or officer change: Paul j. clancy and ian bell to join align technology board of directors

Open the sourceReported by SEC EDGAR, sec.gov, 18 November 2026, by SEC EDGAR

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Align Technology (Nasdaq: ALGN) disclosed in a November 18, 2026 Form 8-K that its board appointed Paul J. Clancy, former CFO of Alexion Pharmaceuticals and Biogen, as a director effective immediately, and Ian Bell, SVP and COO of Alcon, effective December 10, 2026. Clancy brings more than 30 years of biopharma finance and strategy experience, including a decade as Biogen's CFO, while Bell adds commercial, manufacturing, quality and regulatory operating expertise from Alcon. Chairman Kevin Conroy said the additions complement the board's strengths as Align executes its strategy and pursues long-term growth. The appointments expand oversight of the Tempe, Arizona-based maker of Invisalign clear aligners and iTero scanners as it navigates the global dental and orthodontic device market. Investors will watch whether the new directors' healthcare and operational backgrounds shape capital allocation or margin priorities ahead of the company's next earnings update.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR's report. It can get details wrong, so check the source.

Named in this story

Align Technology (ALGN), Paul J. Clancy, Ian Bell, Kevin Conroy, Alexion Pharmaceuticals, Biogen Inc., Alcon Inc.

A linked name opens that asset's sentiment page.